NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Psyence Biomedical Ltd. (PBM) Stock Analysis

Psyence Biomedical Ltd. (PBM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PBM

$4.54

+$0.11 (+2.48%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBM with… →

PBM Key Statistics

As of Sep 4, 2026
Trading
Open
$4.38
Previous Close
$4.43
Day's Range
4.33–4.71
52-Week Range
1.92–216.41
Volume
27.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.73
Valuation
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.83
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.94M−785.56%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−95.50%
Dividend and dates
Avg Volume
77.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PBM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.57%
2025−95.54%
2024−99.70%
2023−10.12%
2022+3.73%
2021 (partial year)+0.10%

As of September 4, 2026.

PBM Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.94M—
2024$0.00$1.01M—
2023$0.00−$51.16M—
2022$0.00−$3.21M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$5.95M−$6.94M—
2024$0.00—−$3.66M$1.01M—
2023$0.00—−$43.35M−$51.16M—
2022$0.00—−$3.23M−$3.21M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

PBM Valuation vs Biotechnology Median

Median of 656 stocks
MetricPBMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The record here covers Psyence Biomedical Ltd., ticker PBM. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12.

The most recent close on file for PBM is $4.54, dated September 4, 2026. That is +$0.11 (+2.48%) against the previous close. The 52-week range on file runs from $1.92 to $216.41. The latest close sits 136.46% above that 52-week low.

Financial Health

In fiscal 2025, Psyence Biomedical Ltd. reported revenue of $0.00. The same year closed with a net loss of $6.94M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −12.83.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.73. Annualized volatility over the trailing 4 years is 160.85%. Over the trailing twelve months the price has returned −95.50%. Measured over 3 years, that is −97.42% a year compounded.

Growth & Income

The record shows no dividend for PBM.

The strongest complete calendar year on file is 2022 at +3.73%; the weakest is 2024 at −99.70%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −84.57% year to date.

Peer Comparison

Psyence Biomedical Ltd. (PBM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Psyence Biomedical Ltd. PBM — —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Psyence Biomedical Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Psyence Biomedical Ltd.

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Visit website →